Edward Fargis Sells 4,394 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) EVP Edward Fargis sold 4,394 shares of the stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $23.15, for a total transaction of $101,721.10. Following the transaction, the executive vice president directly owned 88,660 shares of the company’s stock, valued at approximately $2,052,479. This trade represents a 4.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Privia Health Group Stock Performance

Shares of PRVA stock opened at $22.07 on Thursday. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The firm’s 50 day moving average price is $22.97 and its 200-day moving average price is $23.60. The firm has a market cap of $2.73 billion, a P/E ratio of 129.82, a P/E/G ratio of 1.42 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The business had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the previous year, the firm posted $0.21 earnings per share. The company’s revenue was up 17.4% on a year-over-year basis. As a group, research analysts predict that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Fresh quarterly results showed an earnings and revenue beat: Q4 EPS $0.25 vs. consensus $0.04 and revenue $541.2M (vs. $516.6M est.), with revenue up ~17% YoY — evidence of durable top-line growth that supports the company’s longer-term growth story. Earnings & company page
• Positive Sentiment: Analyst sentiment remains constructive: multiple firms (JPMorgan, RBC, Wolfe, BMO) have issued Outperform/Overweight views and raised price targets (consensus ~ $31), providing upside vs. current levels. That analyst support can limit downside and attract buyer interest. Analyst notes
• Positive Sentiment: Institutional buying reported (e.g., RBC, AQR, Intech added shares recently) and very high institutional ownership (~94%) — institutional inflows can stabilize the stock and are a backstop for larger pullbacks. Institutional holdings
• Neutral Sentiment: Technical/valuation context: 50-day ~$23.00, 200-day ~$23.61, 52‑week range $18.77–$26.51; current multiples are elevated (P/E >100), so the stock is sensitive to execution and guidance. Chart & technicals
• Negative Sentiment: Insider selling by the CEO — Parth Mehrotra sold ~63,439 shares across March 6 and March 9 (aggregate proceeds ≈ $1.46M). Large CEO sales are often viewed negatively by the market even if done for non-firm reasons. CEO Form 4
• Negative Sentiment: CFO David Mountcastle sold 11,006 shares across March 6 and March 9 (~$253k), reducing his stake — additional insider sales from senior finance leadership adds to downward pressure. CFO Form 4
• Negative Sentiment: EVP Edward Fargis sold ~9,343 shares across the two dates (~$215k), trimming his position — multiple concurrent insider sales by the C-suite increases perceived selling pressure. EVP Form 4

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Weiss Ratings reissued a “hold (c)” rating on shares of Privia Health Group in a research report on Monday, December 29th. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a report on Tuesday, January 6th. JPMorgan Chase & Co. lifted their price target on shares of Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, BMO Capital Markets initiated coverage on shares of Privia Health Group in a report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Privia Health Group has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PRVA. Vanguard Group Inc. raised its position in shares of Privia Health Group by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after acquiring an additional 607,447 shares in the last quarter. Durable Capital Partners LP increased its stake in Privia Health Group by 1.8% in the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after purchasing an additional 203,842 shares during the last quarter. State Street Corp raised its holdings in Privia Health Group by 1.5% during the second quarter. State Street Corp now owns 4,171,069 shares of the company’s stock worth $95,935,000 after purchasing an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. lifted its position in shares of Privia Health Group by 1.8% during the 4th quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company’s stock worth $91,147,000 after buying an additional 69,691 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Privia Health Group by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock valued at $66,738,000 after buying an additional 31,204 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.